A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Bradley Corr,  MD

Bradley Corr, MD

Study ID

Protocol Number: 21-4100

More information available at ClinicalTrials.gov: NCT04092270

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers